Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357544 | 0.77 | KDM4E (0.42) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL18505960 | 0.73 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL25959289 | 0.72 | — | — | |
| SCHEMBL21486173 | 0.71 | — | — | |
| SCHEMBL16013908 | 0.69 | — | — | |
| SCHEMBL25800862 | 0.68 | KDM4E (0.30) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25900495 | 0.68 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL7076028 | 0.67 | DPP4 (0.31) | — | |
| SCHEMBL26141892 | 0.67 | SMN1; SMN2 (0.32) | — | |
| Acetonitrile SCHEMBL10334319 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 3535/4885MEN1 815/4885ALDH1A1 4437/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 3535/4885MEN1 815/4885ALDH1A1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.